Omacor (Omega-3-Acid Ethyl Esters 90)

Omacor is a prescription omega‑3 fatty acid that lowers elevated triglyceride levels through modulation of lipid metabolism:

• Severe hypertriglyceridaemia: reduces triglycerides and helps meet target levels.
• Familial hypercholesterolemia (adjunctive therapy): supports overall lipid profile improvement.
• Mixed dyslipidaemia: contributes to lowering triglyceride concentrations alongside other lipid‑lowering agents.

• Omacor provides a high‑purity source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters. After oral absorption, the ethyl esters are hydrolysed to free EPA and DHA, which inhibit hepatic very‑low‑density lipoprotein (VLDL) synthesis and increase beta‑oxidation of fatty acids, resulting in reduced plasma triglyceride concentrations.

Adverse reactions to Omacor are generally dose‑related and may vary in frequency.

Common Side Effects

• Fish‑like aftertaste.
• Mild gastrointestinal discomfort (nausea, dyspepsia, abdominal pain).
• Diarrhoea.
• Flatulence.
• Headache.

Serious or Rare Side Effects

• Acute pancreatitis.
• Severe allergic reactions (anaphylaxis, angio‑edema).
• Elevated liver enzymes.
• Bleeding complications, especially when combined with anticoagulants.
• Hyperglycaemia in susceptible individuals.

When prescribing Omacor, clinicians should consider several safety aspects:

• Monitor triglyceride levels: regular laboratory testing is recommended to assess therapeutic response.
• Assess bleeding risk: evaluate concomitant use of anticoagulants or antiplatelet agents.
• Review hepatic function: baseline liver enzymes should be obtained before initiating therapy.
• Pregnancy and lactation: use only if the potential benefit outweigh  
• Store at below 25°C: keep in the original packaging, protect  

• A